Stem definition | Drug id | CAS RN |
---|---|---|
beta-lactamase inhibitors | 2572 | 89786-04-9 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 77 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 66.49 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.26 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 4.81 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.70 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.97 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 22, 1993 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Thrombocytopenia | 105.21 | 18.96 | 114 | 7794 | 127559 | 50469657 |
Sepsis | 75.19 | 18.96 | 98 | 7810 | 132827 | 50464389 |
Pyrexia | 66.79 | 18.96 | 168 | 7740 | 380035 | 50217181 |
Acute kidney injury | 65.49 | 18.96 | 123 | 7785 | 227935 | 50369281 |
Respiratory failure | 59.10 | 18.96 | 72 | 7836 | 91109 | 50506107 |
Eosinophilia | 54.98 | 18.96 | 35 | 7873 | 18617 | 50578599 |
Multiple organ dysfunction syndrome | 54.20 | 18.96 | 52 | 7856 | 50285 | 50546931 |
Pancytopenia | 53.88 | 18.96 | 66 | 7842 | 83964 | 50513252 |
Leukopenia | 51.53 | 18.96 | 58 | 7850 | 67470 | 50529746 |
Renal failure | 50.23 | 18.96 | 72 | 7836 | 106561 | 50490655 |
Toxic epidermal necrolysis | 48.85 | 18.96 | 34 | 7874 | 20958 | 50576258 |
Dermatitis exfoliative generalised | 47.43 | 18.96 | 18 | 7890 | 3108 | 50594108 |
Septic shock | 45.15 | 18.96 | 50 | 7858 | 57125 | 50540091 |
Rash maculo-papular | 43.74 | 18.96 | 35 | 7873 | 26606 | 50570610 |
Disseminated intravascular coagulation | 40.44 | 18.96 | 28 | 7880 | 17107 | 50580109 |
Platelet count decreased | 38.87 | 18.96 | 62 | 7846 | 100664 | 50496552 |
Tubulointerstitial nephritis | 38.61 | 18.96 | 26 | 7882 | 15185 | 50582031 |
Rash morbilliform | 34.75 | 18.96 | 14 | 7894 | 2832 | 50594384 |
Arthralgia | 34.14 | 18.96 | 13 | 7895 | 438689 | 50158527 |
Haemoglobin decreased | 32.01 | 18.96 | 65 | 7843 | 127151 | 50470065 |
Pleural effusion | 31.23 | 18.96 | 50 | 7858 | 81404 | 50515812 |
Heparin-induced thrombocytopenia | 30.28 | 18.96 | 14 | 7894 | 3951 | 50593265 |
Fatigue | 30.22 | 18.96 | 40 | 7868 | 707561 | 49889655 |
Drug reaction with eosinophilia and systemic symptoms | 29.89 | 18.96 | 29 | 7879 | 28395 | 50568821 |
Agranulocytosis | 28.64 | 18.96 | 25 | 7883 | 21396 | 50575820 |
Nephropathy toxic | 28.58 | 18.96 | 17 | 7891 | 8012 | 50589204 |
Toxic skin eruption | 28 | 18.96 | 19 | 7889 | 11232 | 50585984 |
Pseudomonal sepsis | 27.93 | 18.96 | 11 | 7897 | 2096 | 50595120 |
Drug ineffective | 26.90 | 18.96 | 55 | 7853 | 819278 | 49777938 |
Acute generalised exanthematous pustulosis | 26.90 | 18.96 | 17 | 7891 | 8921 | 50588295 |
Linear IgA disease | 25.64 | 18.96 | 9 | 7899 | 1245 | 50595971 |
Joint swelling | 25.37 | 18.96 | 4 | 7904 | 245282 | 50351934 |
Prothrombin time prolonged | 24.59 | 18.96 | 16 | 7892 | 8822 | 50588394 |
Headache | 24.39 | 18.96 | 26 | 7882 | 506509 | 50090707 |
Drug intolerance | 24.00 | 18.96 | 3 | 7905 | 219101 | 50378115 |
Platelet count increased | 23.64 | 18.96 | 19 | 7889 | 14521 | 50582695 |
Alopecia | 23.18 | 18.96 | 5 | 7903 | 245042 | 50352174 |
Aspergillus infection | 23.13 | 18.96 | 14 | 7894 | 6807 | 50590409 |
White blood cell count decreased | 22.93 | 18.96 | 54 | 7854 | 116668 | 50480548 |
Fall | 22.77 | 18.96 | 12 | 7896 | 334920 | 50262296 |
Neutropenia | 22.37 | 18.96 | 62 | 7846 | 147903 | 50449313 |
Leukocytosis | 21.81 | 18.96 | 22 | 7886 | 22557 | 50574659 |
Blood creatinine increased | 21.67 | 18.96 | 41 | 7867 | 76119 | 50521097 |
Haemolytic anaemia | 21.49 | 18.96 | 15 | 7893 | 9277 | 50587939 |
Abdominal discomfort | 21.36 | 18.96 | 5 | 7903 | 231636 | 50365580 |
Dizziness | 21.30 | 18.96 | 14 | 7894 | 346355 | 50250861 |
Hypokalaemia | 20.99 | 18.96 | 44 | 7864 | 87948 | 50509268 |
Acinetobacter infection | 20.87 | 18.96 | 8 | 7900 | 1419 | 50595797 |
Stevens-Johnson syndrome | 20.66 | 18.96 | 21 | 7887 | 21731 | 50575485 |
Product contamination microbial | 20.17 | 18.96 | 5 | 7903 | 205 | 50597011 |
Febrile neutropenia | 20.07 | 18.96 | 46 | 7862 | 97621 | 50499595 |
Brain oedema | 19.76 | 18.96 | 16 | 7892 | 12354 | 50584862 |
Streptococcal infection | 19.41 | 18.96 | 11 | 7897 | 4737 | 50592479 |
Anaemia | 19.06 | 18.96 | 84 | 7824 | 252372 | 50344844 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Tubulointerstitial nephritis | 96.68 | 17.12 | 66 | 10290 | 17577 | 29546594 |
Acute kidney injury | 95.67 | 17.12 | 254 | 10102 | 265013 | 29299158 |
Thrombocytopenia | 84.35 | 17.12 | 161 | 10195 | 134662 | 29429509 |
Sepsis | 79.14 | 17.12 | 162 | 10194 | 142520 | 29421651 |
Pyrexia | 69.19 | 17.12 | 239 | 10117 | 287383 | 29276788 |
Lymphocyte count abnormal | 65.99 | 17.12 | 19 | 10337 | 608 | 29563563 |
Multiple organ dysfunction syndrome | 58.70 | 17.12 | 90 | 10266 | 63026 | 29501145 |
Clostridial infection | 46.87 | 17.12 | 23 | 10333 | 3292 | 29560879 |
Platelet count decreased | 44.53 | 17.12 | 107 | 10249 | 104565 | 29459606 |
Disseminated intravascular coagulation | 43.97 | 17.12 | 44 | 10312 | 19936 | 29544235 |
Agranulocytosis | 41.50 | 17.12 | 43 | 10313 | 20297 | 29543874 |
Renal tubular necrosis | 40.04 | 17.12 | 36 | 10320 | 14279 | 29549892 |
Rash | 39.72 | 17.12 | 151 | 10205 | 189668 | 29374503 |
Stevens-Johnson syndrome | 39.41 | 17.12 | 38 | 10318 | 16459 | 29547712 |
Septic shock | 39.35 | 17.12 | 75 | 10281 | 62485 | 29501686 |
Neutropenia | 38.28 | 17.12 | 117 | 10239 | 131594 | 29432577 |
Drug reaction with eosinophilia and systemic symptoms | 38.13 | 17.12 | 48 | 10308 | 27944 | 29536227 |
Dizziness | 35.79 | 17.12 | 11 | 10345 | 189673 | 29374498 |
Cholestasis | 34.80 | 17.12 | 42 | 10314 | 23420 | 29540751 |
Choroiditis | 34.50 | 17.12 | 13 | 10343 | 975 | 29563196 |
Respiratory failure | 32.73 | 17.12 | 91 | 10265 | 97040 | 29467131 |
Nephropathy toxic | 31.97 | 17.12 | 28 | 10328 | 10728 | 29553443 |
Renal failure | 31.36 | 17.12 | 102 | 10254 | 118497 | 29445674 |
Clostridium difficile colitis | 30.74 | 17.12 | 30 | 10326 | 13182 | 29550989 |
Heparin-induced thrombocytopenia | 30.56 | 17.12 | 20 | 10336 | 4959 | 29559212 |
Congenital pneumonia | 29.98 | 17.12 | 7 | 10349 | 95 | 29564076 |
Blood creatinine increased | 29.92 | 17.12 | 81 | 10275 | 85021 | 29479150 |
Eosinophilia | 25.52 | 17.12 | 35 | 10321 | 22126 | 29542045 |
Pneumonia staphylococcal | 24.28 | 17.12 | 14 | 10342 | 2771 | 29561400 |
Fatigue | 23.77 | 17.12 | 47 | 10309 | 316774 | 29247397 |
Transplant rejection | 23.48 | 17.12 | 22 | 10334 | 9190 | 29554981 |
Alanine aminotransferase increased | 23.41 | 17.12 | 66 | 10290 | 70878 | 29493293 |
Subclavian artery occlusion | 23.38 | 17.12 | 6 | 10350 | 123 | 29564048 |
Neutrophil count increased | 22.86 | 17.12 | 27 | 10329 | 14715 | 29549456 |
Spontaneous haematoma | 22.80 | 17.12 | 8 | 10348 | 489 | 29563682 |
Hepatic failure | 22.59 | 17.12 | 40 | 10316 | 31472 | 29532699 |
Chills | 22.24 | 17.12 | 65 | 10291 | 71235 | 29492936 |
Aspartate aminotransferase increased | 22.14 | 17.12 | 58 | 10298 | 59667 | 29504504 |
Haemodialysis | 22.04 | 17.12 | 22 | 10334 | 9932 | 29554239 |
Leukopenia | 21.90 | 17.12 | 55 | 10301 | 55148 | 29509023 |
Blood alkaline phosphatase increased | 21.59 | 17.12 | 37 | 10319 | 28369 | 29535802 |
Dialysis | 21.57 | 17.12 | 22 | 10334 | 10186 | 29553985 |
Pancytopenia | 21.48 | 17.12 | 71 | 10285 | 83097 | 29481074 |
Lymphocyte count | 21.48 | 17.12 | 5 | 10351 | 67 | 29564104 |
Death | 21.41 | 17.12 | 56 | 10300 | 342028 | 29222143 |
Headache | 21.07 | 17.12 | 18 | 10338 | 173989 | 29390182 |
Rash erythematous | 20.36 | 17.12 | 31 | 10325 | 21531 | 29542640 |
Organ failure | 20.34 | 17.12 | 11 | 10345 | 1925 | 29562246 |
Acute respiratory distress syndrome | 20.30 | 17.12 | 32 | 10324 | 22903 | 29541268 |
Autoimmune haemolytic anaemia | 20.13 | 17.12 | 14 | 10342 | 3834 | 29560337 |
Drug eruption | 20.12 | 17.12 | 27 | 10329 | 16714 | 29547457 |
Hepatic function abnormal | 19.82 | 17.12 | 43 | 10313 | 39216 | 29524955 |
Blood bilirubin increased | 19.30 | 17.12 | 39 | 10317 | 33854 | 29530317 |
Gamma-glutamyltransferase increased | 19.24 | 17.12 | 34 | 10322 | 26703 | 29537468 |
Rash maculo-papular | 18.93 | 17.12 | 32 | 10324 | 24257 | 29539914 |
Anaphylactic reaction | 18.49 | 17.12 | 34 | 10322 | 27539 | 29536632 |
Respiratory distress | 18.35 | 17.12 | 37 | 10319 | 32069 | 29532102 |
Dermatitis exfoliative | 17.65 | 17.12 | 16 | 10340 | 6409 | 29557762 |
Intraocular pressure increased | 17.39 | 17.12 | 14 | 10342 | 4775 | 29559396 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 153.04 | 16.76 | 327 | 14621 | 448913 | 64034871 |
Thrombocytopenia | 137.79 | 16.76 | 211 | 14737 | 223590 | 64260194 |
Tubulointerstitial nephritis | 122.81 | 16.76 | 81 | 14867 | 30828 | 64452956 |
Sepsis | 114.30 | 16.76 | 197 | 14751 | 230144 | 64253640 |
Pyrexia | 94.81 | 16.76 | 314 | 14634 | 558330 | 63925454 |
Multiple organ dysfunction syndrome | 81.98 | 16.76 | 109 | 14839 | 101304 | 64382480 |
Septic shock | 81.68 | 16.76 | 111 | 14837 | 105326 | 64378458 |
Renal failure | 78.00 | 16.76 | 146 | 14802 | 181542 | 64302242 |
Eosinophilia | 73.73 | 16.76 | 65 | 14883 | 38011 | 64445773 |
Drug reaction with eosinophilia and systemic symptoms | 66.38 | 16.76 | 72 | 14876 | 54145 | 64429639 |
Clostridial infection | 61.73 | 16.76 | 28 | 14920 | 5091 | 64478693 |
Fatigue | 59.36 | 16.76 | 52 | 14896 | 748678 | 63735106 |
Rash maculo-papular | 58.52 | 16.76 | 63 | 14885 | 46963 | 64436821 |
Agranulocytosis | 58.04 | 16.76 | 57 | 14891 | 38172 | 64445612 |
Nephropathy toxic | 55.62 | 16.76 | 40 | 14908 | 17474 | 64466310 |
Respiratory failure | 55.30 | 16.76 | 118 | 14830 | 161065 | 64322719 |
Heparin-induced thrombocytopenia | 53.76 | 16.76 | 30 | 14918 | 8449 | 64475335 |
Dizziness | 52.85 | 16.76 | 17 | 14931 | 430146 | 64053638 |
Pancytopenia | 51.57 | 16.76 | 107 | 14841 | 143202 | 64340582 |
Platelet count decreased | 51.01 | 16.76 | 117 | 14831 | 167594 | 64316190 |
Leukopenia | 50.61 | 16.76 | 87 | 14861 | 101155 | 64382629 |
Disseminated intravascular coagulation | 50.54 | 16.76 | 49 | 14899 | 32299 | 64451485 |
Stevens-Johnson syndrome | 50.02 | 16.76 | 50 | 14898 | 34199 | 64449585 |
Arthralgia | 48.43 | 16.76 | 21 | 14927 | 442239 | 64041545 |
Transplant rejection | 46.87 | 16.76 | 36 | 14912 | 17365 | 64466419 |
Renal tubular necrosis | 45.32 | 16.76 | 39 | 14909 | 22071 | 64461713 |
Neutropenia | 44.30 | 16.76 | 139 | 14809 | 239485 | 64244299 |
Headache | 44.06 | 16.76 | 35 | 14913 | 529432 | 63954352 |
Toxic epidermal necrolysis | 43.12 | 16.76 | 48 | 14900 | 37118 | 64446666 |
Clostridium difficile colitis | 40.22 | 16.76 | 40 | 14908 | 27183 | 64456601 |
Acute generalised exanthematous pustulosis | 39.88 | 16.76 | 30 | 14918 | 14028 | 64469756 |
Choroiditis | 38.52 | 16.76 | 13 | 14935 | 1074 | 64482710 |
Dialysis | 37.04 | 16.76 | 31 | 14917 | 16889 | 64466895 |
Rash | 36.95 | 16.76 | 206 | 14742 | 458343 | 64025441 |
Fall | 36.65 | 16.76 | 26 | 14922 | 416800 | 64066984 |
Joint swelling | 35.89 | 16.76 | 4 | 14944 | 215378 | 64268406 |
Cholestasis | 32.84 | 16.76 | 46 | 14902 | 44826 | 64438958 |
Autoimmune haemolytic anaemia | 31.67 | 16.76 | 20 | 14928 | 7056 | 64476728 |
Toxic skin eruption | 31.61 | 16.76 | 30 | 14918 | 19254 | 64464530 |
Blood creatinine increased | 31.03 | 16.76 | 85 | 14863 | 135697 | 64348087 |
Weight increased | 30.85 | 16.76 | 6 | 14942 | 213342 | 64270442 |
Acute respiratory distress syndrome | 30.12 | 16.76 | 41 | 14907 | 38894 | 64444890 |
Hypotension | 29.89 | 16.76 | 170 | 14778 | 380804 | 64102980 |
Dermatitis exfoliative generalised | 29.73 | 16.76 | 18 | 14930 | 5898 | 64477886 |
Nasopharyngitis | 29.46 | 16.76 | 5 | 14943 | 196068 | 64287716 |
Prothrombin time prolonged | 28.73 | 16.76 | 26 | 14922 | 15715 | 64468069 |
Drug intolerance | 27.79 | 16.76 | 5 | 14943 | 187987 | 64295797 |
Alopecia | 27.79 | 16.76 | 3 | 14945 | 165687 | 64318097 |
Haemodialysis | 26.92 | 16.76 | 26 | 14922 | 17051 | 64466733 |
Linear IgA disease | 26.74 | 16.76 | 13 | 14935 | 2761 | 64481023 |
Systemic candida | 26.23 | 16.76 | 16 | 14932 | 5313 | 64478471 |
Nephritis | 26.16 | 16.76 | 14 | 14934 | 3632 | 64480152 |
Blood bilirubin increased | 25.57 | 16.76 | 47 | 14901 | 57506 | 64426278 |
Anaphylactic reaction | 25.53 | 16.76 | 52 | 14896 | 68612 | 64415172 |
Haemoglobin decreased | 25.50 | 16.76 | 101 | 14847 | 194962 | 64288822 |
Enterococcal infection | 25.49 | 16.76 | 23 | 14925 | 13843 | 64469941 |
Acinetobacter infection | 25.28 | 16.76 | 12 | 14936 | 2417 | 64481367 |
Interstitial lung disease | 25.19 | 16.76 | 64 | 14884 | 97668 | 64386116 |
Blood alkaline phosphatase increased | 25.06 | 16.76 | 46 | 14902 | 56233 | 64427551 |
Renal impairment | 24.61 | 16.76 | 78 | 14870 | 134939 | 64348845 |
Aspartate aminotransferase increased | 24.44 | 16.76 | 72 | 14876 | 119716 | 64364068 |
Subclavian artery occlusion | 24.37 | 16.76 | 6 | 14942 | 159 | 64483625 |
Rash morbilliform | 24.19 | 16.76 | 15 | 14933 | 5126 | 64478658 |
Neutrophil count decreased | 23.59 | 16.76 | 54 | 14894 | 77142 | 64406642 |
Weight decreased | 23.57 | 16.76 | 19 | 14929 | 285720 | 64198064 |
White blood cell count decreased | 23.33 | 16.76 | 85 | 14863 | 157752 | 64326032 |
Respiratory distress | 22.33 | 16.76 | 42 | 14906 | 52289 | 64431495 |
Pseudomembranous colitis | 22.27 | 16.76 | 14 | 14934 | 4902 | 64478882 |
Rash erythematous | 21.96 | 16.76 | 40 | 14908 | 48593 | 64435191 |
Pain in extremity | 21.64 | 16.76 | 23 | 14925 | 303062 | 64180722 |
Petechiae | 21.50 | 16.76 | 24 | 14924 | 18602 | 64465182 |
Alanine aminotransferase increased | 21.50 | 16.76 | 76 | 14872 | 138955 | 64344829 |
Febrile neutropenia | 21.26 | 16.76 | 93 | 14855 | 187564 | 64296220 |
Neutrophilic dermatosis | 21.11 | 16.76 | 7 | 14941 | 548 | 64483236 |
Abdominal discomfort | 20.98 | 16.76 | 8 | 14940 | 182314 | 64301470 |
Staphylococcal infection | 20.79 | 16.76 | 40 | 14908 | 50638 | 64433146 |
Dermatitis exfoliative | 20.68 | 16.76 | 18 | 14930 | 10334 | 64473450 |
Hepatic failure | 20.65 | 16.76 | 42 | 14906 | 55352 | 64428432 |
Pseudomonas infection | 20.57 | 16.76 | 23 | 14925 | 17860 | 64465924 |
Antibiotic level above therapeutic | 20.43 | 16.76 | 7 | 14941 | 606 | 64483178 |
Aplasia pure red cell | 19.97 | 16.76 | 15 | 14933 | 6999 | 64476785 |
Hepatic cytolysis | 19.57 | 16.76 | 20 | 14928 | 14029 | 64469755 |
International normalised ratio increased | 19.52 | 16.76 | 51 | 14897 | 79116 | 64404668 |
Pleural effusion | 19.41 | 16.76 | 69 | 14879 | 126490 | 64357294 |
Extravasation blood | 19.28 | 16.76 | 6 | 14942 | 383 | 64483401 |
Acanthosis | 19.03 | 16.76 | 6 | 14942 | 400 | 64483384 |
White blood cell count increased | 18.88 | 16.76 | 45 | 14903 | 65969 | 64417815 |
Aspergillus infection | 18.73 | 16.76 | 21 | 14927 | 16358 | 64467426 |
Spontaneous haematoma | 18.71 | 16.76 | 8 | 14940 | 1263 | 64482521 |
Hepatic function abnormal | 18.56 | 16.76 | 44 | 14904 | 64269 | 64419515 |
Drug abuse | 18.55 | 16.76 | 4 | 14944 | 132370 | 64351414 |
Blood culture positive | 18.44 | 16.76 | 15 | 14933 | 7853 | 64475931 |
Muscle spasms | 18.32 | 16.76 | 5 | 14943 | 141018 | 64342766 |
Leukocytosis | 18.27 | 16.76 | 32 | 14916 | 37708 | 64446076 |
Organ failure | 18.11 | 16.76 | 11 | 14937 | 3622 | 64480162 |
Clostridium difficile infection | 17.95 | 16.76 | 31 | 14917 | 36132 | 64447652 |
Purpura | 17.85 | 16.76 | 21 | 14927 | 17225 | 64466559 |
Insomnia | 17.80 | 16.76 | 12 | 14936 | 197824 | 64285960 |
Skin oedema | 17.71 | 16.76 | 8 | 14940 | 1440 | 64482344 |
Neuralgic amyotrophy | 17.55 | 16.76 | 5 | 14943 | 235 | 64483549 |
Moraxella infection | 17.48 | 16.76 | 6 | 14942 | 522 | 64483262 |
Haemolytic anaemia | 17.37 | 16.76 | 20 | 14928 | 16033 | 64467751 |
Contusion | 16.91 | 16.76 | 3 | 14945 | 113962 | 64369822 |
Klebsiella infection | 16.88 | 16.76 | 18 | 14930 | 13263 | 64470521 |
None
Source | Code | Description |
---|---|---|
ATC | J01CG02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase inhibitors |
FDA MoA | N0000000202 | beta Lactamase Inhibitors |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D065093 | beta-Lactamase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:35441 | antiinfective agents |
CHEBI has role | CHEBI:35625 | beta-lactamase inhibitors |
FDA EPC | N0000175930 | beta Lactamase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Abscess of liver | indication | 27916005 | |
Peritonitis | indication | 48661000 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Appendicitis | indication | 74400008 | DOID:8337 |
Abdominal abscess | indication | 75100008 | |
Cholecystitis | indication | 76581006 | DOID:1949 |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Bacterial cystitis | indication | 424551004 | |
Nosocomial pneumonia | indication | 425464007 | |
Sepsis caused by Haemophilus influenzae | indication | 447685007 | |
Sepsis caused by Serratia | indication | 449084002 | |
Bacterial pyelonephritis | indication | 838353009 | |
Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
E. Coli Complicated Appendicitis | indication | ||
Staphylococcus Nosocomial Pneumonia | indication | ||
Diabetic Foot Infection | indication | ||
Bacteroides Peritonitis | indication | ||
E. Coli Endometritis | indication | ||
E. Coli Appendicitis | indication | ||
Inflammatory Disease of Female Pelvic Organs | indication | ||
E. Coli Pelvic Inflammatory Disease | indication | ||
Bacteroides Complicated Appendicitis | indication | ||
Bacteroides Appendicitis | indication | ||
Complicated Skin and Skin Structure Infection | indication | ||
E. Coli Peritonitis | indication | ||
Ecthyma gangrenosum | off-label use | 17732003 | |
Infection of bone | off-label use | 111253001 | |
Sepsis of the newborn | off-label use | 206376005 | |
Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis | off-label use | ||
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.19 | acidic |
pKa2 | 0.39 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 40MG BASE/ML;EQ 5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | WYETH PHARMS | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 40MG BASE/ML;EQ 5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | WYETH PHARMS | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | ZOSYN IN PLASTIC CONTAINER | WYETH PHARMS | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | ZOSYN IN PLASTIC CONTAINER | WYETH PHARMS | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | WYETH PHARMS | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | WYETH PHARMS | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | METHODS FOR TREATING BACTERIAL INFECTIONS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | METHODS OF TREATING BACTERIAL ILLNESSES |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8685957 | Sept. 27, 2032 | METHODS OF TREATING BACTERIAL ILLNESSES |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | Dec. 19, 2019 | NEW CHEMICAL ENTITY |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | Dec. 19, 2024 | GENERATING ANTIBIOTIC INCENTIVES NOW |
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | April 21, 2025 | NEW PATIENT POPULATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-lactamase TEM | Enzyme | INHIBITOR | IC50 | 6.60 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | IC50 | 6.53 | WOMBAT-PK | |||||
Beta-lactamase | Enzyme | IC50 | 7.82 | WOMBAT-PK | |||||
Beta-lactamase | Enzyme | IC50 | 5.47 | CHEMBL | |||||
Beta-lactamase SHV-1 | Enzyme | IC50 | 6.65 | CHEMBL | |||||
Beta-lactamase 1 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
IMI-1; IMI-1 carbapenemase | Enzyme | IC50 | 7.52 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.09 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.72 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.03 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.40 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.40 | CHEMBL | |||||
Carbapenem-hydrolizing beta-lactamase SFC-1 | Enzyme | IC50 | 5.16 | CHEMBL | |||||
Carbepenem-hydrolyzing beta-lactamase KPC | Enzyme | Ki | 4.13 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.02 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.70 | CHEMBL | |||||
Beta-lactamase SHV-1 | Enzyme | IC50 | 6.96 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.62 | CHEMBL | |||||
Beta-lactamase GES-13 | Enzyme | IC50 | 7.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.10 | CHEMBL | |||||
Class D beta-lactamase | Unclassified | IC50 | 6.80 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.30 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.66 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 5.70 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 5.70 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.29 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.40 | CHEMBL |
ID | Source |
---|---|
D00660 | KEGG_DRUG |
89785-84-2 | SECONDARY_CAS_RN |
4020843 | VANDF |
C0075870 | UMLSCUI |
CHEBI:9421 | CHEBI |
TAZ | PDB_CHEM_ID |
CHEMBL404 | ChEMBL_ID |
DB01606 | DRUGBANK_ID |
CHEMBL1439 | ChEMBL_ID |
D000078142 | MESH_DESCRIPTOR_UI |
123630 | PUBCHEM_CID |
10789 | IUPHAR_LIGAND_ID |
6340 | INN_ID |
SE10G96M8W | UNII |
221167 | RXNORM |
30782 | MMSL |
5543 | MMSL |
d04404 | MMSL |
004398 | NDDF |
004399 | NDDF |
410931003 | SNOMEDCT_US |
427652008 | SNOMEDCT_US |
96007008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | NDA | 27 sections |
Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | NDA | 27 sections |
Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | NDA | 27 sections |
Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | NDA | 27 sections |
Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | NDA | 27 sections |
Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | NDA | 27 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1.50 g | INTRAVENOUS | ANDA | 25 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 25 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 25 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 25 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3390 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3110 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3113 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3114 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3117 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-3180 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-9210 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-9213 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-9214 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 22607-012 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 22607-034 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 22607-056 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 22607-679 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4.50 g | INTRAVENOUS | ANDA | 26 sections |
Piperacillin, Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-164 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 30 sections |
Piperacillin, Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-165 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 30 sections |
Piperacillin, Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-166 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 30 sections |
Piperacillin, Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-175 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 30 sections |
Piperacillin, Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-176 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 30 sections |